期刊文献+

大肠杆菌来源的人乳头瘤病毒11型病毒样颗粒的制备及其免疫原性 被引量:7

Expression,purification and immunogenicity of human papillomavirus type 11 virus-like particles from Escherichia coli
原文传递
导出
摘要 【目的】利用大肠杆菌表达系统制备人乳头瘤病毒11型病毒样颗粒(HPV11VLPs),并对其免疫原性和所诱导中和抗体的型交叉反应性进行研究。【方法】在大肠杆菌ER2566中非融合表达HPV11-L1蛋白,并通过离子交换层析,疏水相互作用层析其进行纯化。纯化后的HPV11-L1经体外组装形成病毒样颗粒,通过动态光散射,透射电镜检测其形态,并通过多种HPV型别假病毒中和实验评价HPV11VLPs的免疫原性及型交叉反应性。【结果】HPV11-L1蛋白在大肠杆菌中可以以可溶形式表达。经过硫酸铵沉淀、离子交换和疏水相互作用色谱纯化,目的蛋白纯度能够达到95%以上。纯化的HPV11-L1蛋白去除还原剂DTT后,能够在体外自发组装成为直径约50nm、与天然病毒颗粒形态高度相似的VLPs。动物实验结果显示,该病毒样颗粒在小鼠体内的中和抗体半数有效剂量(ED50)为0.031μg,在小鼠体内可诱导高达106的中和抗体滴度,这些中和抗体与HPV6有较好的交叉反应,与HPV18有一定的交叉反应,而与HPV16没有明显的交叉反应,这一结果与分子进化树的分析相一致。【结论】本研究利用原核表达系统获得了具有较高免疫原性的HPV11VLPs,为HPV11预防性疫苗的研制奠定了良好的基础。 [ Objective] To produce human papillomavirus type 11 virus-like particles (HPV11 VLPs) from Escherichia coli and to investigate its immunogenicity and type cross neutralization nature. [ Methods ] We expressed the major capsid protein of HPV11 (HPV11-L1) in Escherichia coli ER2566 in non fusion fashion and purified by amino sulfate precipitation, ion-exchange chromatography and hydrophobic interaction chromatography, sequentially. Then we removed the reductant DTr to have the purified HPV11-L1 self-assemble into VLPs in vitro. We investigated the morphology of these VLPs with dynamic light scattering and transmission electron microscopy. We assayed the immunogenicity of the resultant HPV11 VLPs by vaccinations on mice and evaluated by HPV6/ll/16/18 pseudovirion neutralization cell models. [Results] We expressed HPV11-L1 in Escherichia coli with two forms, soluble and inclusion body. The soluble HPV11 L1 with over 95 % purity can self assemble to VLPs in high efficiency. Morphologically, these VLPs were globular, homogeneous and with a diameter of - 50 nm, which is quite .similar with native HPVll virions. The half effective dosage (ED50) of HPVll VLPs is 0.031 μg, and the maximum titer of neutralizing antibody elicited is averaged to 106. The cross neutralization activity (against HPV6/16/18) of the anti-HPV11 serum was found to have exact correlation to the inter-type homology in amino acid alignment. [ Conclusion] We can provide HPV11 VLPs with highly immunogenicity from prokaryote expression system, which may pave a new way for research and development of prophylactic vaccine for HPV11.
出处 《微生物学报》 CAS CSCD 北大核心 2009年第11期1527-1533,共7页 Acta Microbiologica Sinica
基金 国家“863计划”--国家高技术研究发展计划重点项目(2006AA020905) 国家自然科学基金(30500092) 科技部工程中心建设项目(2005DC105006) 教育部新世纪优秀人才培养计划(NCET-05-0567)~~
关键词 人乳头瘤病毒11型 大肠杆菌表达系统 病毒样颗粒 免疫原性 型交叉中和 human papillomavirus type 11 Escherichia coli virus-like particle immunogenicity cross neutralization
  • 相关文献

参考文献13

  • 1Insinga RP, Dasbach E J, Elbasha EH, et al. Incidence and duration of cervical human papillomavirus 6, 11, 16, and 18 infections in young women: an evaluation from multiple analytic perspectives. Cancer Epidemiol Biomarkers Prevention, 2007, 16(4) : 709 - 715.
  • 2Roden RB, Greenstone HL, Kirnbauer R, et al. In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype. Journal of Virology, 1996, 70(9) :5875 - 5883.
  • 3Zhou J, Sun XY, Stenzel Dj, et al. Expression of vaceinia recombinant HPV 16 L1 and L20RF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology, 1991, 185(1) : 251 - 257.
  • 4罗文新,张军,杨海杰,李少伟,谢小燕,逄淑强,李少菁,夏宁邵.一种带增强子的原核高效表达载体的构建及初步应用[J].生物工程学报,2000,16(5):578-581. 被引量:34
  • 5卢五迅,程通,李少伟,潘晖榕,沈文通,陈毅歆,张涛,郑舟,张军,夏宁邵.人乳头瘤病毒16型假病毒中和实验的建立和初步应用[J].生物工程学报,2006,22(6):990-995. 被引量:13
  • 6Ruiz W, Mcclements WL Jansen KU, et al. Kinetics and isotype profile of antibody responses in rhesus macaques induced following vaccination with HPV 6, 11, 16 and 18 Ll-virus-like particles formulated with or without Merck aluminum adjuvant. Journal of Immune Based Therapies and Vaccines, 2005, 3(1): 2.
  • 7Villa LL, Costa RL Petta CA, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/ 11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. British Journal of Cancer, 2006, 95( 11 ) : 1459 - 1466.
  • 8Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women : a randomised controlled trial. Lancet, 2004, 364(9447) : 1757 - 1765.
  • 9Rose RC, Reichman RC, Bonnez W. Human papillomavirus (HPV) type 11 recombinant virus-like particles induce the formation of neutralizing antibodies and detect HPV-specific antibodies in human sera. Journal of General Virology, 1994, 75 (8): 2075-2079.
  • 10Cook JC, Joyce JG, George HA, et al. Purification of virus-like particles of recombinant human papillomavirus type 11 major capsid protein L1 from Saecharomyees cerevisiae. Protein Expression and Purification, 1999, 17 (3) : 477 - 484.

二级参考文献26

  • 1萨姆布鲁克J 金冬雁等(译).分子克隆操作指南(第2版)[M].北京:科学出版社,1992..
  • 2朱玉贤 李毅.现代分子生物学[M].北京:高等教育出版社,1998.195.
  • 3Hosfield T,Biotechniques,1999年,27卷,1期,58页
  • 4Wyborski D L,Protein Expr Purif,1999年,16卷,1期,1页
  • 5何忠效,现代生物技术概论,1999年,9页
  • 6朱玉贤,现代分子生物学,1998年,195页
  • 7金冬雁(译),分子克隆实验指南(第2版),1992年
  • 8Munoz N, Bosch FX, Castellsague X et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective, lnt J Cancer, 2004, 111(2):278 - 285
  • 9White WI, Wilson SD, Bonnez W et al. In vitro infection and type-restricted antibody-mediated neutralization of authentic human papillomavirus type 16. J Virol, 1998, 72(2):959- 964
  • 10Meyers C, Frattini MG, Hudson JB et al. Biosynthesis of human papillomavirus from a continuous cell line upon epithelial differentiation. Science, 1992, 257(5072): 971-973

共引文献43

同被引文献77

  • 1卢五迅,程通,李少伟,潘晖榕,沈文通,陈毅歆,张涛,郑舟,张军,夏宁邵.人乳头瘤病毒16型假病毒中和实验的建立和初步应用[J].生物工程学报,2006,22(6):990-995. 被引量:13
  • 2Zui Hausen H. Papillomaviruses in anogenital cancer as a model to understand the role of viruses in human cancers. Cancer Res, 1989,49:4677.
  • 3Schiller JT, Castellsague X, Villa LL, et al. An update of prophylactic human papillomavirusLI virus like particle vaccine clinical trial results. Vaccine,2008,19 ;53-61.
  • 4项铮.我国宫颈癌疫苗研制有望成世界第三.科技日报,2011年2月17日.
  • 5Kawana K, Matsumoto K, Yoshikawa H, et al. A surface immunodeterminant of human PV type 16 minor capsid protein L2. Viroloyg,1998,245 :353-359.
  • 6Kawana K, Yoshikawa H, Taketani Y, et al. Common neutralization epitone in minor protein L2 of human PV types 16 and 6. Viroloyg, 1999,73:6188-6190.
  • 7Gambhlra R, Karanam B, Jagu S, ct al. A protective and broadly cross-neutralizing epitope of human PV L2. Virology, 2007,81 : 13927-13931.
  • 8Jagu S, Karanam B, Gambhira R, et al. Concatenated muhitype L2 fusion proteins candidate prophylactic pan-human papillomavirus vaccines. J Natl Cancer Inst,2009,101 : 782-792.
  • 9Rubio I, Bolchi A, Moretto N, et al. Potent anti-HPV immune responses induced by tandem repeats of the HPV16 1-2 ( 20-38 ) peptide displayed on bacterial thioredoxin. Vaccine, 2009,27: 1949-1956.
  • 10Rubio I,Seitz H, Canali E, et al. The N-terminal region of the human papillomavirus L2 protein contains overlapping binding sites for neutralizing cross-neutralizing and non-neutralizing antibodies. Virology,2011,409:348-359.

引证文献7

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部